Novo Nordisk: supported by a broker upgrade

(CercleFinance.com) - Novo Nordisk climbs over 3% in Copenhagen, in the wake of an upgrade from 'neutral' to 'buy' on the pharmaceutical company's stock, despite a sharply lowered target price from DKK 1100 to DKK 750.


The broker lowers its target after CagriSema, but considers the wave of selling on the stock exaggerated. Novo remains the most exciting growth story in the pharmaceutical industry in the EU, and is now reasonably valued", it believes.

Copyright (c) 2025 CercleFinance.com. All rights reserved.